Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

Published:2018-04-04 Issue:4 Volume:12 Page:202-209
ISSN:1574-8847
Container-title:Current Clinical Pharmacology
language:en
Short-container-title:CCP

Author:

Karras Spyridon N.¹,Rapti Eleni¹,Koufakis Theocharis¹,Kyriazou Angeliki¹,Goulis Dimitrios G.²,Kotsa Kalliopi¹

Affiliation:

1. Division of Endocrinology and Metabolism - Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

2. Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between variants in TCF7L2 , CTRB1/2 , and GLP-1R genes and response to therapy with glucagon-like peptide-1 receptor agonists;Postgraduate Medicine;2024-02-17

2. Pharmakogenetik neuer Glukosespiegelsenker: eine Chance für die Präzisionsmedizin?;Die Diabetologie;2023-01-24

3. Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes;Journal of Personalized Medicine;2022-03-09

4. Precision Medicine in Endocrinology Practice;Precision Medicine in Clinical Practice;2022

5. High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination;Clinics and Practice;2021-12-21